Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Latest developments in radiopharmaceutical therapies

Ian A. Wilson • 12 Nov 2021
SITC 2021
Gastrointestinal Cancer General Genitourinary Cancer Gynecological Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Antibodies

Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, gives an overview of ongoing work in radiopharmaceutical therapies. Specifically discussed is the pairing of a CD8 antibody fragment with a radioisotope to produce targeted radiotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Ian A. Wilson

0:41
Next steps for the CD8 ImmunoPET minibody
Ian A. Wilson • 12 Nov 2021
1:09
Addressing unmet clinical needs with the CD8 ImmunoPET minibody
Ian A. Wilson • 12 Nov 2021

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals